Melanoma driver mutations and immune therapy

Douglas B. Johnson*, Christine M. Lovly, Ryan J. Sullivan, Richard D. Carvajal, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations’ impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss our findings and their implications for melanoma therapeutics.

Original languageEnglish (US)
Article numbere1051299
Issue number5
StatePublished - May 3 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Melanoma driver mutations and immune therapy'. Together they form a unique fingerprint.

Cite this